Combination drug therapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic esophageal squamous cell carcinoma that has returned or spread, and you have already tried at least one standard treatment that failed.
- You can provide a tumor tissue sample (from a previous biopsy or a new one) for testing.
- You are able to care for yourself (ECOG performance status 0-2) and are expected to live at least 3 months.
- Your organ function is adequate, including blood counts, liver, kidney, and heart function (no severe heart problems).
- You do not have conditions that increase your risk of bleeding or perforation in the esophagus, and you do not have untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the experimental drug becotatug vedotin to standard chemotherapy and radiation therapy can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma. It may help shrink the tumor or slow its growth.
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.